» Articles » PMID: 39682717

Neurodevelopment of Autism: Critical Periods, Stress and Nutrition

Overview
Journal Cells
Publisher MDPI
Date 2024 Dec 17
PMID 39682717
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disability that presents significant challenges in communication and behavior. ASD prevalence exceeds 2% among eight-year-old children and is at similar levels globally. We propose that critical periods during fetal development and early postnatal years establish the conditions for either neurotypical development or the emergence of autism through mechanisms that influence immune function or delay neuronal development. One critical period is characterized by the requirement for folate, a crucial methyl donor needed for DNA regulation. Insufficient folate availability has been linked to the risk of developing ASD. Another critical period may be affected by oxidative stress or inflammation of the fetal brain, potentially due to inadequate microglial immunity, which can lead to CNS inflammatory changes that disrupt typical neurodevelopment. We suggest that early supplementation with reduced folate and taurine during both the fetal and postnatal stages may be effective in mitigating the severity of ASD symptoms by promoting neurotypical development through these critical neurodevelopmental periods.

References
1.
Ramirez-Celis A, Croen L, Yoshida C, Alexeeff S, Schauer J, Yolken R . Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability. Mol Psychiatry. 2022; 27(9):3760-3767. PMC: 9708563. DOI: 10.1038/s41380-022-01633-4. View

2.
Tu W, Chen H, He J . Application of LC-MS/MS analysis of plasma amino acids profiles in children with autism. J Clin Biochem Nutr. 2012; 51(3):248-9. PMC: 3491252. DOI: 10.3164/jcbn.12-45. View

3.
Parenti M, Slupsky C . Disrupted Prenatal Metabolism May Explain the Etiology of Suboptimal Neurodevelopment: A Focus on Phthalates and Micronutrients and their Relationship to Autism Spectrum Disorder. Adv Nutr. 2024; 15(9):100279. PMC: 11375317. DOI: 10.1016/j.advnut.2024.100279. View

4.
Hosoya K, Fujita K, Tachikawa M . Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate. Drug Metab Pharmacokinet. 2008; 23(4):285-92. DOI: 10.2133/dmpk.23.285. View

5.
Meltzer A, Van de Water J . The Role of the Immune System in Autism Spectrum Disorder. Neuropsychopharmacology. 2016; 42(1):284-298. PMC: 5143489. DOI: 10.1038/npp.2016.158. View